Previous close | 44.66 |
Open | 44.95 |
Bid | 43.34 x 600 |
Ask | 43.47 x 400 |
Day's range | 43.32 - 44.95 |
52-week range | 34.32 - 54.44 |
Volume | |
Avg. volume | 1,209,931 |
Market cap | 6.509B |
Beta (5Y monthly) | 0.40 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.48 |
Earnings date | 01 May 2024 - 06 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 55.75 |
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Monday, April 8th at 10:00 a.m. Eastern Time to discuss the olezarsen Phase 3 Balance study results in patients with familial chylomicronemia syndrome (FCS) presented at the 2024 American College of Cardiology Annual Meeting.
Ionis' (IONS) collaboration revenues enable it to invest in its wholly-owned pipeline. This is expected to enhance Ionis' already diverse revenue streams.
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will present positive Phase 3 Balance results in patients with familial chylomicronemia syndrome (FCS) for the company's lead independent, investigational medicine, olezarsen, at the 2024 American College of Cardiology (ACC) Annual Meeting in Atlanta, Georgia.